ATE477340T1 - Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens - Google Patents

Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens

Info

Publication number: ATE477340T1
Authority: AT; Austria
Prior art keywords: frmd3; diagnosing; treating cancer; cancer based; gene
Prior art date: 2006-04-24

Application number

AT07728400T

Other languages

English (en)

Inventor

Peter Angel

Bettina Hartenstein

Doreen Haase

Michael Meister

Thomas Muley

Original Assignee

Dkfz Krebsforschungszentrum

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-24

Filing date

2007-04-23

Publication date

2010-08-15

2007-04-23 Application filed by Dkfz Krebsforschungszentrum filed Critical Dkfz Krebsforschungszentrum

2010-08-15 Application granted granted Critical

2010-08-15 Publication of ATE477340T1 publication Critical patent/ATE477340T1/de

Links

101001030545 Homo sapiens FERM domain-containing protein 3 Proteins 0.000 title abstract 4
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
102100038514 FERM domain-containing protein 3 Human genes 0.000 abstract 3
108091033319 polynucleotide Proteins 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 3
239000002157 polynucleotide Substances 0.000 abstract 3
229920001184 polypeptide Polymers 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Marine Sciences & Fisheries (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT07728400T 2006-04-24 2007-04-23 Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens ATE477340T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06112978A EP1849878A1 (de)	2006-04-24	2006-04-24	Mittel und Verfahren zur Diagnose und Behandlung von Krebs, basierend auf dem FRMD3-Gen
PCT/EP2007/053943 WO2007122213A2 (en)	2006-04-24	2007-04-23	Means and methods for diagnosing and treating cancer based on the frmd3 gene

Publications (1)

Publication Number	Publication Date
ATE477340T1 true ATE477340T1 (de)	2010-08-15

Family

ID=36888977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07728400T ATE477340T1 (de)	2006-04-24	2007-04-23	Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens

Country Status (5)

Country	Link
US (1)	US20100151588A1 (de)
EP (2)	EP1849878A1 (de)
AT (1)	ATE477340T1 (de)
DE (1)	DE602007008393D1 (de)
WO (1)	WO2007122213A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9879930B2 (en) *	2016-01-19	2018-01-30	Charles B. Cassels	Compact action spring and buffer assembly
US10690425B2 (en)	2017-12-22	2020-06-23	Charles B. Cassels	Firearm with locked breech rotating bolt pistol
CN116327892B (zh) *	2022-12-23	2025-10-14	郑州大学	抗结直肠癌的蛋白及其基因片段

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060275794A1 (en) *	2005-03-07	2006-12-07	Invitrogen Corporation	Collections of matched biological reagents and methods for identifying matched reagents
WO2006124022A1 (en) *	2005-05-13	2006-11-23	Vanandel Research Institute	Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
TW200730825A (en) *	2005-10-21	2007-08-16	Genenews Inc	Method and apparatus for correlating levels of biomarker products with disease

2006
- 2006-04-24 EP EP06112978A patent/EP1849878A1/de not_active Withdrawn
2007
- 2007-04-23 AT AT07728400T patent/ATE477340T1/de not_active IP Right Cessation
- 2007-04-23 DE DE602007008393T patent/DE602007008393D1/de active Active
- 2007-04-23 US US12/298,295 patent/US20100151588A1/en not_active Abandoned
- 2007-04-23 WO PCT/EP2007/053943 patent/WO2007122213A2/en not_active Ceased
- 2007-04-23 EP EP07728400A patent/EP2010673B1/de not_active Not-in-force

Also Published As

Publication number	Publication date
US20100151588A1 (en)	2010-06-17
WO2007122213A3 (en)	2007-12-21
DE602007008393D1 (de)	2010-09-23
EP2010673A2 (de)	2009-01-07
EP2010673B1 (de)	2010-08-11
WO2007122213A2 (en)	2007-11-01
EP1849878A1 (de)	2007-10-31

Similar Documents

Publication	Publication Date	Title
EP2320057A4 (de)	2016-10-26	Diagnosevorrichtung für kraftstoffsparenden betrieb, diagnosesystem für kraftstoffsparenden betrieb, antriebsaggregatsteuerung, vorrichtung zur auswertung von kraftstoffsparendem betrieb und diagnoseverfahren für kraftstoffsparenden betrieb
ATE526421T1 (de)	2011-10-15	Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
WO2010015607A3 (en)	2010-04-01	Method of evaluating oral cancer risk in human
ATE410524T1 (de)	2008-10-15	Verfahren und nukleinsäuren für die analyse von zellulären proliferationsstörungen
NO20091736L (no)	2009-06-30	IL-17-reseptor A-antigenbindende proteiner
ATE223727T1 (de)	2002-09-15	Erkennung und modulierung von iaps und naip zur diagnose und behandlung von proliferativen erkrankungen
ATE549418T1 (de)	2012-03-15	Verfahren und nukleinsäuren zur analyse proliferativer zellerkrankungen
EP1904630A4 (de)	2009-10-21	Verfahren zur behandlung und diagnose von epilepsie durch nachweisen von mutationen im scn1a-gen
ATE493661T1 (de)	2011-01-15	Mittel und verfahren zur prognose oder diagnose von diabetes typ ii
ATE488251T1 (de)	2010-12-15	Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE431426T1 (de)	2009-05-15	Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
ATE371738T1 (de)	2007-09-15	Mittel und verfahren zur diagnose und behandlung affektiver störungen
EP3522899A4 (de)	2020-05-06	Verbindungen und zusammensetzungen zur behandlung von leishmaniose und verfahren zur diagnose und behandlung damit
WO2014059196A3 (en)	2014-06-12	Diagnosis and treatment of sma and smn deficiency
ATE477340T1 (de)	2010-08-15	Mittel und verfahren zur diagnose und behandlung von krebs auf basis des frmd3-gens
EP1869212A4 (de)	2009-09-23	Verwendung von id4 zur diagnose und behandlung von krebs
EP1928614A4 (de)	2009-06-17	Verfahren zur diagnose von infektionen
EP2291544A4 (de)	2012-09-12	Genetische veränderungen auf chromosomen 21q, 6q und 15q sowie verfahren zur verwendung davon bei der diagnose und behandlung von typ-i-diabetes
ATE480641T1 (de)	2010-09-15	Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE602006012585D1 (de)	2010-04-15	Verfahren zur Förderung von Michael-additionsreaktionen
EA201100253A1 (ru)	2011-10-31	Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
DE602006014106D1 (de)	2010-06-17	Verfahren zur diagnose von prostatakrebs
DE60037126D1 (de)	2007-12-27	POLYMORPHISMEN DES MENSCHLICHEN HPXR Gens UND IHRE ANWENDUNG IN DIAGNOSE UND THERAPIE
WO2009080017A3 (de)	2009-10-29	Markersequenzen für neurodegenerative erkrankungen und deren verwendung
ATE528650T1 (de)	2011-10-15	Verfahren zum nachweis und zur diagnose einer infektion mit trypanosoma cruzi

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties